Fact Sheet
October 2010
This Fact Sheet provides a broader research perspective and background guiding
the genesis and development of IntraTherapies Neurosystemic Medicine and
Epigenetic Cancer Therapeutics initiatives.
IntraTherapies Institute is initiating multi-site treatment programs for its
oncology platform defined as IECT-IntraTherapies Epigenetic Cancer Therapeutics.
The program utilizes known FDA approved compounds redirected to clinical targets
previously unaddressed or unrecognized in the domains of age-related
degenerative disorders within the construct of human senescence, and late stage
cancer therapeutics.
IntraTherapies involvement with epigenetics originated in 2001 with a platform
of neurometabolic / neuroendocrine regulating compounds intended to modulate the
pathophysiologies of age related degenerative disorders and also confer
neuroprotective benefits over time. Epigenetics refers to the reversible,
heritable changes in gene regulation that occur without a change in DNA
sequence. These changes, known as gene expression, can be addressed and
regulated by pharmacologic processes. IECT developer Nathan Sassover identifies
this as DNA-PGP: DNA Programmable Genetic Pharmacology. He has further unified
IntraTherapies integrative approach within a personalized medicine framework he
defines as Epigenetic Neurobiology.
The clinical pathways focusing on neurosystemic therapeutic and preventive
protocols has evolved under the guidance of inventor and IECT developer Nathan
Sassover and protocol designer, IntraTherapies Medical Advisor, Dr. Brent
Treiger, MD, a research oncologist with a diverse fifteen year drug development
background. Dr. Treiger is the developer of the ovarian cancer drug, Doxal. The
impetus for launching the IECT cancer treatment program follows initial highly
encouraging outcome in a clinical study of one Advanced Breast Cancer patient.
Following eight weeks of outpatient treatment, PET /CT scan radiology reports
confirmed significant tumor reduction, further corroborated by radiology
oncologists clinical reports, as well as hematology analysis confirming improved
cancer blood titers.
In the same time period, October 2008 - January 2009, parallel initial studies in
a male patient with advanced Metastatic adenocarcinoma of the colon, also
yielded encouraging meaningful reduction in key cancer titer blood levels as
evidenced by hematology lab data confirmed by the attending physician
administering the protocol during the eight week period.
Following these indicative outcomes, IntraTherapies has focused on deeper
clinical inquiry related to possible relevance of IECT as a pathway-specific
protocol for other solid tumor and hematologic cancers.
The IntraTherapies oncology platform is defined as :
IECT-IntraTherapies Epigenetic Cancer Therapeutics:
Clinical Protocols based on Molecular Cancer Genetics and DNA Programmable
Genetic Pharmacology to Inhibit the Growth, Replication and Proliferation of
Human
Cancer Cells.
An eight month research initiative was focused on developing a basis for
intervention in a total of six (6) solid tumor categories which serve as the
basis for a broader Cancer Epigenetics Program with the objective of validating
evidence-based safety / efficacy across the accepted ASCO (American Society of
Clinical Oncologists) standards of PFS - Progression Free Survival / OS-Overall
Survival, and QOL-Quality of Life measurable criteria.
The company has also established its IECT clinical management team which brings
the requisite hematology / oncology experience to the task of initiating and
administering this epigenetic treatment platform which utilizes known FDA
approved compounds.
IECT- IntraTherapies Epigenetic Cancer Therapeutics Protocols target six solid
tumor cancer lines and two hematological malignancies.
Advanced Stage III and IV Breast Cancer
Metastatic (Stage IV) Colon Cancer
Metastatic (Stage IV) Castration-Resistant Prostate Cancer (CRPC)
Advanced (Stage III and IV) Non Small Cell Lung Cancer (NSCLC)
Advanced (Stage III and IV) Ovarian Cancer
Metastatic (Stage IV) Renal Cell Carcinoma (Kidney Cancer
Hematologic Malignancies:
MDS - Myelodysplastic Syndrome - CML AML Leukemia
The multi-city cancer epigenetics program was initiated with World Cancer
Institute, intended as a public forum and informational resource focusing on
preventive and integrative cancer therapeutics, based on scientifically
validated research within known medical research centers and corresponding
publication of scientific studies in globally recognized peer-reviewed medical
journals and professional medical associations and clinical presentations.
IntraTherapies primary objectives with the IECT programs presented here are to
advance the clinical potential of DNA Demethylation and other Epigenetic cancer
interventional and preventive modalities and techniques utilized singly or in
conjunction with metronomic very low dose chemotherapy, further optimized by
drug delivery methods which are easier to accommodate for patients with late
stage cancers, where treatment outcomes are of diminishing effect in second,
third and fourth line administration of conventional chemotherapy.
Provide a daily treatment regimen with functional transparency, clinically
verified efficacy with evidence-based reduction in patient toxicity levels. In
parallel, utilize clinically validated QOL instruments to assess long term
quality of life factors attending extended treatment of late stage cancer
patients without compromise of safety.
Within a majority of healthcare settings, it is an established statistically
recognized fact that 80% of chemotherapeutic pharmaceutical and
biopharmaceutical interventional treatments are not effective. In conjunction
with World Cancer Institute, the broader objective is bringing a clinical focus
and new pathways of currently accessible treatment to the most medically
challenging condition known to mankind… human cancer.
Often times a clinical initiative can find itself well timed - in tune with an
emerging consensus, a turning point which can have the unintended ‘side effect’
and benefit of serendipity. Such is the case with the Obama administration’s
view of the importance of advancing the creation of research programs to treat
and hopefully cure cancer, while, in the President's words, "…bypassing the
‘choke point’ of clinical trials to bring important medical discoveries
forward."
In summary, the enlarging healthcare crisis in the US and increased focus
redefining the 'War on Cancer' after marginal outcome over the past thirty
years, warrants greatly accelerated attention in addressing the global
progression of all forms of cancer and the life science developments which are
seeking avenues of medically validated prevention and intervention.